Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an announcement.
Shanghai Bio-Heart Biological Technology, through its subsidiary Shanghai AngioCare Medical Technology, has completed registration of its Iberis Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in Thailand, with support from partner Biosensors International Group. The Iberis renal denervation system, which already holds CE marking in Europe, is currently the only RDN product approved globally for both transradial and transfemoral approaches, enabling potentially safer, more effective and lower-cost outpatient procedures and strengthening the company’s international expansion strategy.
AngioCare’s strategic partnership with Biosensors spans the European Union, the Asia-Pacific region and Latin America, leveraging Biosensors’ global sales network and cardiology presence to accelerate commercialization of the Iberis system. The Thailand registration marks another step in broadening access to minimally invasive hypertension treatments, reinforcing Shanghai Bio-Heart’s positioning in the competitive cardiovascular device market while expanding its footprint in emerging healthcare markets.
The most recent analyst rating on (HK:2185) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shanghai Bio-Heart Biological Technology Co., Ltd. Class H stock, see the HK:2185 Stock Forecast page.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. is a China-based medical technology company focused on cardiovascular and renal interventional devices, including its flagship Iberis renal denervation system. Through its subsidiary Shanghai AngioCare Medical Technology, the group targets global markets such as Europe, the Asia-Pacific region and Latin America via strategic commercialization partnerships.
Average Trading Volume: 312,924
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.13B
For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.